Biogen Inc
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psorias… Read more
Biogen Inc (BIIB) - Total Assets
Latest total assets as of December 2025: $29.44 Billion USD
Based on the latest financial reports, Biogen Inc (BIIB) holds total assets worth $29.44 Billion USD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Biogen Inc - Total Assets Trend (1985–2025)
This chart illustrates how Biogen Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Biogen Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Biogen Inc's total assets of $29.44 Billion consist of 30.5% current assets and 69.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 10.2% |
| Accounts Receivable | $1.87 Billion | 6.3% |
| Inventory | $2.17 Billion | 7.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $9.18 Billion | 31.2% |
| Goodwill | $6.49 Billion | 22.1% |
Asset Composition Trend (1985–2025)
This chart illustrates how Biogen Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biogen Inc's current assets represent 30.5% of total assets in 2025, a decrease from 66.4% in 1985.
- Cash Position: Cash and equivalents constituted 10.2% of total assets in 2025, down from 62.4% in 1985.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 53.0% of total assets, an increase from 2.0% in 1985.
- Asset Diversification: The largest asset category is intangible assets at 31.2% of total assets.
Biogen Inc Competitors by Total Assets
Key competitors of Biogen Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Novartis AG
PINK:NVSEF
|
USA | $115.49 Billion |
|
Pfizer Inc
NYSE:PFE
|
USA | $208.73 Billion |
|
AbbVie Inc
NYSE:ABBV
|
USA | $133.96 Billion |
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
|
Zhejiang Zhenyuan Share Co Ltd
SHE:000705
|
China | CN¥3.03 Billion |
|
Hunan Jingfeng Pharmaceutical
SHE:000908
|
China | CN¥877.99 Million |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
|
China | CN¥2.58 Billion |
|
Zhejiang Haisen Pharmaceutical Co. Ltd. A
SHE:001367
|
China | CN¥1.52 Billion |
Biogen Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Biogen Inc generates 0.33x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Biogen Inc generates $ 4.39 in net profit.
Biogen Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.68 | 1.35 | 2.12 |
| Quick Ratio | 2.03 | 0.90 | 1.75 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $5.62 Billion | $ 1.93 Billion | $ 3.55 Billion |
Biogen Inc - Advanced Valuation Insights
This section examines the relationship between Biogen Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.56 |
| Latest Market Cap to Assets Ratio | 0.91 |
| Asset Growth Rate (YoY) | 5.0% |
| Total Assets | $29.44 Billion |
| Market Capitalization | $26.81 Billion USD |
Valuation Analysis
Near Book Valuation: The market values Biogen Inc's assets close to their book value ( 0.91x), suggesting investors view the company's assets at approximately fair value.
Positive Asset Growth: Biogen Inc's assets grew by 5.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Biogen Inc (1985–2025)
The table below shows the annual total assets of Biogen Inc from 1985 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $29.44 Billion | +4.96% |
| 2024-12-31 | $28.05 Billion | +4.49% |
| 2023-12-31 | $26.84 Billion | +9.33% |
| 2022-12-31 | $24.55 Billion | +2.83% |
| 2021-12-31 | $23.88 Billion | -3.01% |
| 2020-12-31 | $24.62 Billion | -9.60% |
| 2019-12-31 | $27.23 Billion | +7.69% |
| 2018-12-31 | $25.29 Billion | +6.92% |
| 2017-12-31 | $23.65 Billion | +3.39% |
| 2016-12-31 | $22.88 Billion | +17.29% |
| 2015-12-31 | $19.50 Billion | +36.24% |
| 2014-12-31 | $14.32 Billion | +20.68% |
| 2013-12-31 | $11.86 Billion | +17.11% |
| 2012-12-31 | $10.13 Billion | +11.94% |
| 2011-12-31 | $9.05 Billion | +11.83% |
| 2010-12-31 | $8.09 Billion | -5.37% |
| 2009-12-31 | $8.55 Billion | +0.86% |
| 2008-12-31 | $8.48 Billion | -1.74% |
| 2007-12-31 | $8.63 Billion | +0.89% |
| 2006-12-31 | $8.55 Billion | +2.22% |
| 2005-12-31 | $8.37 Billion | -8.72% |
| 2004-12-31 | $9.17 Billion | -3.56% |
| 2003-12-31 | $9.50 Billion | +373.54% |
| 2002-12-31 | $2.01 Billion | +16.61% |
| 2001-12-31 | $1.72 Billion | +20.20% |
| 2000-12-31 | $1.43 Billion | +12.04% |
| 1999-12-31 | $1.28 Billion | +38.20% |
| 1998-12-31 | $924.72 Million | +13.63% |
| 1997-12-31 | $813.83 Million | +28.25% |
| 1996-12-31 | $634.57 Million | +35.25% |
| 1995-12-31 | $469.20 Million | +24.17% |
| 1994-12-31 | $377.86 Million | +5.84% |
| 1993-12-31 | $357.00 Million | +14.72% |
| 1992-12-31 | $311.20 Million | +22.96% |
| 1991-12-31 | $253.10 Million | +59.68% |
| 1990-12-31 | $158.50 Million | +9.16% |
| 1989-12-31 | $145.20 Million | +79.48% |
| 1988-12-31 | $80.90 Million | +0.25% |
| 1987-12-31 | $80.70 Million | -20.02% |
| 1986-12-31 | $100.90 Million | +17.60% |
| 1985-12-31 | $85.80 Million | -- |